Trial Profile
Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China (ROCKI Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors AbbVie
- 21 Jun 2018 Status changed from active, no longer recruiting to completed.
- 31 May 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Jan 2018 Planned End Date changed from 30 Jun 2018 to 12 Jun 2018.